Prof. P Yogeeswari

Dean, Administration
Shri B.K. Birla and Smt. Sarala Birla Chair Professor
Senior Professor, Department of Pharmacy
Chairperson, Institutional Animal Ethics Committee

Alzheimer’s Disease, Anti-Cancer screening, Anti-inflammatory screening, Anticonvulsant screening, Autism spectrum disorder (ASD), Biophysical characterization, CNS Behavioral and cognition screening, Cancer, Dengue virus, Duchenne Muscular Dystrophy, Epilepsy, Fetal Alcohol spectrum disorder (FASD), Fragile X syndrome, Hepatitis C virus, Molecular pharmacology, Nerve conduction velocity, Neurochemical estimations in different regions of brain, Neuropathic pain including Diabetic neuropathy, Neuropathicpain, Neurotoxicity screening, Tuberculosis

Birla Institute of Technology and Science- Pilani, Hyderabad Campus Jawahar Nagar, Shameerpet Mandal, R.R. District, Pin-500078, INDIA

pyogee@hyderabad.bits-pilani.ac.in

+91 40 66303515

Qualification

Ph. D. (Medicinal Chemistry), Institute of Technology, Banaras Hindu University, Varanasi, India, 2001.
Master of Pharmacy (Medicinal Chemistry), Banaras Hindu University, India, 1998.
Bachelor of Pharmacy, The Tamilnadu Dr. M.G.R. Medical University, Chennai, India, 1996 (State Topper, Gold medalist).

Research Interest

Drug Design and Synthesis

· Various New Targets of Neurological disorders that include
i. Neuropathic pain including Diabetic neuropathy
ii. Autism spectrum disorder (ASD)
iii. Fragile X syndrome
iv. Fetal Alcohol spectrum disorder (FASD)
v. Duchenne Muscular Dystrophy
vi. Epilepsy,
vii. Alzheimer’s Disease,

· Various New Targets for
i. Tuberculosis
ii. Hepatitis C virus
iii. Dengue virus
iv. Cancer

Drug Screening
i. Anticonvulsant screening
ii. Neuropathicpain
iii. CNS Behavioral and cognition screening
iv. Neurochemical estimations in different regions of brain
v. Nerve conduction velocity
vi. Anti-Cancer screening
vii. Anti-inflammatory screening
viii. Neurotoxicity screening
ix. Molecular pharmacology
x. Biophysical characterization

Research Collaborations

· National Institute of Health, Bethesda, USA
· National Cancer Institute, USA
· National Institute of Mental Health and Neurosciences, Bangalore, India
· Indian Institute of Science, Bangalore, India.
· National Institute of Immunology, New Delhi, India
· Karolinska Institute, Stockholm, Sweden
· The University of Queensland, Australia
· Department of Ophthalmology & Visual Science, University of Illinois, Chicago, USA
· Dongduk Women's University, Seoul, Korea
· Pasteur Institute, University of Lille, France
· University of KwaZulu Natal, Durban, South Africa
· Federal University of Para, Belem, Brazil
· Bogomoletz Institute of Physiology National Academy of Science, Ukraine
· Faculty of Medicine of Porto, Porto, Portugal
· Instituto Nacional de Ciencia e Technologia em Tuberculosis, MCT/CNPq, Porto Alegre, Brazil
· Incozen Therapeutics Pvt. Ltd, Hyderabad
· Rutger's The State University of New Jersey, New Jersey Medical School, Newark, New Jersey, USA
· Basavatarakam Indo-US Cancer Hospital, Hyderabad, India
· Army College of Dental Sciences, Hyderabad

Publications
Total Publications: 318
Books/Chapters in Book : 4
Research Papers, Reports : 308
Patents: 6
h index: 41
Citations: 6885 (As on 10 July 2018)

CRYSTAL STRUCTURES:

Crystal Structures of the Ligand Designed in our CADD lab published in pdb.
1. 3ZEI: Structure of the Mycobacterium tuberculosis O-Acetylserine Sulfhydrylase (OASS) CysK1 in complex with a small molecule inhibitor5AKWCrystal structure of TNKS2 in complex with 2-(4-chlorophenyl)-1,2,3,4- tetrahydroquinazolin-4-oneCrystal structure of TNKS2 in complex with 2-(4-(propan-2-yl)phenyl)- 1H,2H,3H,4H-pyrido(2,3-d)pyrimidin-4-one
2. Structure of the Mycobacterium tuberculosis O-Acetylserine Sulfhydrylase (OASS) CysK1 in complex with a small molecule inhibitor5AKWCrystal structure of TNKS2 in complex with 2-(4-chlorophenyl)-1,2,3,4- tetrahydroquinazolin-4-oneCrystal structure of TNKS2 in complex with 2-(4-(propan-2-yl)phenyl)- 1H,2H,3H,4H-pyrido(2,3-d)pyrimidin-4-one: Structure of the Mycobacterium tuberculosis O-Acetylserine Sulfhydrylase (OASS) CysK1 in complex with a small molecule inhibitor5AKWCrystal structure of TNKS2 in complex with 2-(4-chlorophenyl)-1,2,3,4- tetrahydroquinazolin-4-oneCrystal structure of TNKS2 in complex with 2-(4-(propan-2-yl)phenyl)- 1H,2H,3H,4H-pyrido(2,3-d)pyrimidin-4-one
3. 5AL1: Crystal structure of TNKS2 in complex with 2-(4-tert-butylphenyl)-1H, 2H,3H,4H-pyrido(2,3-d)pyrimidin-4-one
4. 5AL2: Structure of the Mycobacterium tuberculosis O-Acetylserine Sulfhydrylase (OASS) CysK1 in complex with a small molecule inhibitor5AKWCrystal structure of TNKS2 in complex with 2-(4-chlorophenyl)-1,2,3,4- tetrahydroquinazolin-4-oneCrystal structure of TNKS2 in complex with 2-(4-(propan-2-yl)phenyl)- 1H,2H,3H,4H-pyrido(2,3-d)pyrimidin-4-one
5. 5AL3: Crystal structure of TNKS2 in complex with 2-(2,4-dichlorophenyl)-1- methyl-1H,2H,3H,4H-pyrido(2,3-d)pyrimidin-4-one
6. 5AKU: Crystal structure of TNKS2 in complex with 2-(4-tert-butylphenyl)-1,2, 3,4-tetrahydroquinazolin-4-one
7. 5AL4: Crystal structure of TNKS2 in complex with 2-(4-methylpiperazin-1-yl)- 3,4,5,6,7,8-hexahydroquinazolin-4-one
8. 5AL5: Crystal structure of TNKS2 in complex with 2-(4-((pyridin-4-yl)methyl) piperazin-1-yl)-3,4,5,6,7,8-hexahydroquinazolin-4-one

Click here for more information.

Integrated first degree

Higher Degree

Doctoral Programmes

Student Services

Student Activities

Integrated First Degree

Higher Degree

Doctoral Programmes

WILP

Dubai Campus

Give us your feedback

Upload Screenshot